# Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

> **NCT00731029** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 239 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Thiomersal free trivalent influenza split vaccine 2002/2003
- **BIOLOGICAL:** GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003

## Key facts

- **NCT ID:** NCT00731029
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2003-04
- **Final completion:** —
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2008-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731029, "Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00731029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*